A new molecular multiplex IgE assay for the diagnosis of pollen allergy in Mediterranean countries: A validation study

Fraia, Marco Di; Arasi, Stefania; S, Castelli; Dramburg, Stephanie; Potapova, Ekaterina; Villalta, Danilo; Tripodi, Salvatore; Sfika, Ifigenia; Zicari, Anna Maria; Villella, Valeria; Perna, Serena; Travaglini, Alessandro; Verardo, Pier Luigi; Matricardi, Paolo Maria

doi:10.1111/cea.13264

Cited by 39 publications

(44 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…53 There are several commercially available immuno-solid-phase multiplex allergen arrays: the Thermo Fisher ImmunoCAP ISAC (Immuno-solidphase Allergen Chip), which contains 112 allergens from 51 allergen sources 12 ; the new ImmunoCAP ISAC 112i, with 112 components from 48 allergen sources, where some components have been removed (Hymenoptera components, Pla a 2, Jug r 2) and some others were added (Ana o 3, Can f 4, Can f 6, Cor a 14, Der p 23 and alpha-Gal); the MADx Allergen Explorer (ALEX; containing 282 allergens: 156 extracts and 126 components) 54 ; and the Euroline microstrips. 55 The large number of extracts/ allergens from multiple classes of allergenic sources (Table 2) provides extensive and detailed information about a patient's sensitization profile. 54,56 Other diagnostic tools based on allergen arrays are under development, and new tools will likely be available in the near future.…”

Section: In Vitro Diagnostics Singleplex and Multiplex Measurement Armentioning

confidence: 99%

“…Substantial agreement between MAST and ImmunoCAP was found for inhalant, food, and venom allergens, and it thus represents a valid diagnostic alternative. 55 Finally, epitope mapping will be the real future, provided that a large number of clinical and experimental data become available. Indeed, peptides are recognized by humans in an HLArestricted manner.…”

Section: Available Diagnostic Toolsmentioning

confidence: 99%

See 1 more Smart Citation

A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

Ansotegui¹,

Melioli²,

Canonica³

et al. 2020

World Allergy Organization Journal

Self Cite

View full text Add to dashboard Cite

Precision allergy molecular diagnostic applications (PAMD@) is increasingly entering routine care. Currently, more than 130 allergenic molecules from more than 50 allergy sources are commercially available for in vitro specific immunoglobulin E (sIgE) testing. Since the last publication of this consensus document, a great deal of new information has become available regarding this topic, with over 100 publications in the last year alone. It thus seems quite reasonable to publish an update. It is imperative that clinicians and immunologists specifically trained in allergology keep abreast of the new and rapidly evolving evidence available for PAMD@. PAMD@ may initially appear complex to interpret; however, with increasing experience, the information gained provides relevant information for the allergist. This is especially true for food allergy, Hymenoptera allergy, and for the selection of allergen immunotherapy. Nevertheless, all sIgE tests, including PAMD@, should be evaluated within the framework of a patient's clinical history, because allergen sensitization does not necessarily imply clinical relevant allergies.

show abstract

Section: In Vitro Diagnostics Singleplex and Multiplex Measurement Armentioning

confidence: 99%

Section: Available Diagnostic Toolsmentioning

confidence: 99%

A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

Ansotegui¹,

Melioli²,

Canonica³

et al. 2020

World Allergy Organization Journal

Self Cite

View full text Add to dashboard Cite

show abstract

“…Children (10-18 years) were enrolled in the Department of Pediatrics of "Sandro Pertini" Hospital in Rome (Italy), and adults (19-60 years) were enrolled in the Hospital "S.Maria degli Angeli" of Pordenone (Italy). 27 The recruited patients underwent interviews with standardized questionnaires, skin prick test (SPT), and blood drawing, followed by a second visit, including NS collection. A subset of patients underwent a second blood drawing, performed the same day as the NS sampling (for further details, see Methods in Appendix S1).…”

Section: Study Design and Populationmentioning

confidence: 99%

“…27 Hence, polysensitization to many different pollen sources is typical in patients with SAR living in these areas. 27 This characteristic emerged also in our study population. The repertoire of allergens recognized by IgE in the patients' secretions at a molecular ( Figure 1) and source level ( Figure 2) confirmed a predominance of airborne-specific molecules.…”

Section: Ige Repertoire In Ns and In Serummentioning

confidence: 99%

“…To these ends, we have examined NS and sera of 161 pediatric and adult patients affected by seasonal allergic rhinitis (SAR), participating in a broader study on pollen allergy in Italy. 27 In more detail, we tested specific IgE reactivity to 112 allergenic molecules present on a microarray (ISAC-112TM; TFS) in their NS and sera. To our knowledge, this is the first time that local allergen-specific IgE antibodies have been assessed in NS of such a large population of AR patients using biochip technology.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

IgE antibody repertoire in nasal secretions of children and adults with seasonal allergic rhinitis: A molecular analysis

Arasi

Tripodi

et al. 2020

Pediatric Allergy Immunology

Self Cite

View full text Add to dashboard Cite

Background: There is growing interest both in testing IgE in nasal secretions (NS) and in molecular diagnosis of seasonal allergic rhinitis (SAR). Yet, the reliability of nasal IgE detection with the newest molecular assays has never been assessed in a large cohort of pollen allergic patients.Objective: To investigate with microarray technology and compare the repertoires of specific IgE (sIgE) antibodies in NS and sera of a large population of children and adults with SAR.Methods: Nasal secretions were collected with an absorbent device (Merocel 2000 ® , Medtronic) and a minimal dilution procedure from 90 children and 71 adults with SAR. Total IgE (tIgE) (ImmunoCAP, Thermo Fisher Scientific (TFS)) and sIgE antibodies against 112 allergen molecules (ISAC-112, TFS) were measured in NS and serum.Results: Nasal sIgE was detectable in 68.3% of the patients. The detected nasal sIgE antibodies recognized airborne (88%), vegetable (10%), and animal food or other (<1%) allergen molecules. The prevalence and average levels of sIgE in NS and serum were highly interrelated at population level. A positive nasal sIgE antibody to a given molecule predicted the detection of the same antibody in the patient's serum with a specificity of 99.7% and a sensitivity of 40%. Conclusions:The concentration of sIgE is much lower in nasal secretions than in the serum. sIgE assays with very high analytical sensitivity and sampling methods with minimal dilution will be therefore needed to validate nasal secretions as alternative to serum in testing the sIgE repertoire.This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

show abstract

Heterogeneous validity of daily data on symptoms of seasonal allergic rhinitis recorded by patients using the e‐diary AllergyMonitor®

Dramburg

Perna

Fraia

et al. 2021

Clinical & Translational All

Self Cite

View full text Add to dashboard Cite

Background Patient‐generated symptom and medication scores are essential for diagnostic and therapeutic decisions in seasonal allergic rhinitis (SAR). Previous studies have shown solid consistencies between different scores at population level in real‐life data and trials. For clinicians, the evaluation of individual data quality over time is essential to decide whether to rely on these data in clinical decision‐making. Objective To analyze the consistency of different symptom (SS) and symptom medication scores (SMSs) at individual level in two study cohorts with different characteristics and explore individual patient trajectories over time. Methods Within the pilot phase of the @IT.2020 project on diagnostic synergy of mobile health and molecular IgE assessment in patients with SAR, we analyzed data of 101 children and 93 adults with SAR and instructed them to record their symptoms and medication intake daily via the mobile app AllergyMonitor®. We then assessed the correlation between different SMS and a visual analogue scale (VAS) on the impact of allergy symptoms on daily life at population and individual level. Results At population level, the Rhinoconjunctivitis total symptom score (RTSS) correlated better with VAS than the combined symptom and medication score (CSMS). At individual level, consistency among RTSS and VAS was highly heterogeneous and unrelated to disease severity or adherence to recording. Similar heterogeneity was observed for CSMS and VAS. Conclusions The correlation of clinical information provided by different disease severity scores based on data collected via electronic diaries (e‐diaries), is sufficient at population level, but broadly heterogeneous for individual patients. Consistency of the recorded data must be examined for each patient before remotely collected information is used for clinical decision making.

show abstract

A new molecular multiplex IgE assay for the diagnosis of pollen allergy in Mediterranean countries: A validation study

Cited by 39 publications

References 16 publications

A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

IgE antibody repertoire in nasal secretions of children and adults with seasonal allergic rhinitis: A molecular analysis

Heterogeneous validity of daily data on symptoms of seasonal allergic rhinitis recorded by patients using the e‐diary AllergyMonitor®

Contact Info

Product

Resources

About